IL127487A - Use of thiazolidinone derivatives for the preparation of drugs for the treatment of neurodegenerative diseases - Google Patents

Use of thiazolidinone derivatives for the preparation of drugs for the treatment of neurodegenerative diseases

Info

Publication number: IL127487A
Authority: IL; Israel
Prior art keywords: thiazolidinone; eae; neurodegenerative disorders; cells; disease
Prior art date: 1996-07-11

Application number

IL12748797A

Other languages

English (en)

Hebrew (he)

Other versions

IL127487A0 (en

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-11

Filing date

1997-07-01

Publication date

2002-04-21

1997-07-01 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

1999-10-28 Publication of IL127487A0 publication Critical patent/IL127487A0/xx

2002-04-21 Publication of IL127487A publication Critical patent/IL127487A/en

Links

208000015122 neurodegenerative disease Diseases 0.000 title claims description 21
239000003814 drug Substances 0.000 title claims description 16
208000024827 Alzheimer disease Diseases 0.000 claims abstract description 15
201000006417 multiple sclerosis Diseases 0.000 claims abstract description 10
150000003839 salts Chemical class 0.000 claims abstract description 6
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims abstract description 3
238000011282 treatment Methods 0.000 claims description 20
150000001875 compounds Chemical class 0.000 claims description 12
238000002360 preparation method Methods 0.000 claims description 5
AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims description 2
BAZGFSKJAVQJJI-UHFFFAOYSA-N 2-amino-5-[(3,5-ditert-butyl-4-hydroxyphenyl)methylidene]-1,3-thiazol-4-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C=C2C(N=C(N)S2)=O)=C1 BAZGFSKJAVQJJI-UHFFFAOYSA-N 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
208000006011 Stroke Diseases 0.000 abstract description 7
208000035475 disorder Diseases 0.000 abstract description 6
206010019196 Head injury Diseases 0.000 abstract description 5
201000002491 encephalomyelitis Diseases 0.000 description 33
210000004027 cell Anatomy 0.000 description 19
241001465754 Metazoa Species 0.000 description 18
230000000694 effects Effects 0.000 description 18
241000699670 Mus sp. Species 0.000 description 15
230000034994 death Effects 0.000 description 14
231100000517 death Toxicity 0.000 description 14
238000002474 experimental method Methods 0.000 description 13
241000700159 Rattus Species 0.000 description 11
229940079593 drug Drugs 0.000 description 11
241000282472 Canis lupus familiaris Species 0.000 description 10
230000001186 cumulative effect Effects 0.000 description 9
230000006378 damage Effects 0.000 description 9
239000007924 injection Substances 0.000 description 9
238000002347 injection Methods 0.000 description 9
208000024891 symptom Diseases 0.000 description 9
102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 8
108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 8
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
210000004556 brain Anatomy 0.000 description 6
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
208000014674 injury Diseases 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
239000002953 phosphate buffered saline Substances 0.000 description 6
210000000329 smooth muscle myocyte Anatomy 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
241000282693 Cercopithecidae Species 0.000 description 5
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 5
239000002775 capsule Substances 0.000 description 5
239000002158 endotoxin Substances 0.000 description 5
229920006008 lipopolysaccharide Polymers 0.000 description 5
238000000034 method Methods 0.000 description 5
230000000926 neurological effect Effects 0.000 description 5
241000894007 species Species 0.000 description 5
230000004580 weight loss Effects 0.000 description 5
201000006474 Brain Ischemia Diseases 0.000 description 4
206010008120 Cerebral ischaemia Diseases 0.000 description 4
206010021143 Hypoxia Diseases 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
206010033799 Paralysis Diseases 0.000 description 4
206010008118 cerebral infarction Diseases 0.000 description 4
201000010099 disease Diseases 0.000 description 4
230000002218 hypoglycaemic effect Effects 0.000 description 4
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
230000004770 neurodegeneration Effects 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical group C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 3
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
239000012981 Hank's balanced salt solution Substances 0.000 description 3
208000013016 Hypoglycemia Diseases 0.000 description 3
102000008299 Nitric Oxide Synthase Human genes 0.000 description 3
108010021487 Nitric Oxide Synthase Proteins 0.000 description 3
206010070834 Sensitisation Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
210000004720 cerebrum Anatomy 0.000 description 3
230000001054 cortical effect Effects 0.000 description 3
230000003013 cytotoxicity Effects 0.000 description 3
231100000135 cytotoxicity Toxicity 0.000 description 3
208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
239000008103 glucose Substances 0.000 description 3
230000007954 hypoxia Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000006698 induction Effects 0.000 description 3
210000000274 microglia Anatomy 0.000 description 3
239000000203 mixture Substances 0.000 description 3
230000001537 neural effect Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
230000008313 sensitization Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000008733 trauma Effects 0.000 description 3
230000007082 Aβ accumulation Effects 0.000 description 2
241000588832 Bordetella pertussis Species 0.000 description 2
241000282465 Canis Species 0.000 description 2
206010012289 Dementia Diseases 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
101001018320 Mus musculus Myelin basic protein Proteins 0.000 description 2
108010081690 Pertussis Toxin Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
238000000692 Student's t-test Methods 0.000 description 2
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000032683 aging Effects 0.000 description 2
229940024606 amino acid Drugs 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
230000030833 cell death Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
210000003618 cortical neuron Anatomy 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
208000010726 hind limb paralysis Diseases 0.000 description 2
229960000905 indomethacin Drugs 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000002609 medium Substances 0.000 description 2
210000002418 meninge Anatomy 0.000 description 2
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000009467 reduction Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
238000010186 staining Methods 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
238000012353 t test Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000002110 toxicologic effect Effects 0.000 description 2
238000001262 western blot Methods 0.000 description 2
SLYRGJDSFOCAAI-UHFFFAOYSA-N 1,3-thiazolidin-2-one Chemical compound O=C1NCCS1 SLYRGJDSFOCAAI-UHFFFAOYSA-N 0.000 description 1
PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
AKTXOQVMWSFEBQ-UHFFFAOYSA-N 2-amino-5-[(3,5-ditert-butyl-4-hydroxyphenyl)methylidene]-1,3-thiazol-4-one Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C=C2C(NC(=N)S2)=O)=C1 AKTXOQVMWSFEBQ-UHFFFAOYSA-N 0.000 description 1
102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
206010059245 Angiopathy Diseases 0.000 description 1
102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
206010008190 Cerebrovascular accident Diseases 0.000 description 1
108010058699 Choline O-acetyltransferase Proteins 0.000 description 1
102100023460 Choline O-acetyltransferase Human genes 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
241001269524 Dura Species 0.000 description 1
102000015689 E-Selectin Human genes 0.000 description 1
108010024212 E-Selectin Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
238000006595 Griess deamination reaction Methods 0.000 description 1
241000282412 Homo Species 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
-1 Hydroxypropyl Chemical group 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010021639 Incontinence Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
208000021642 Muscular disease Diseases 0.000 description 1
102000047918 Myelin Basic Human genes 0.000 description 1
101710107068 Myelin basic protein Proteins 0.000 description 1
201000009623 Myopathy Diseases 0.000 description 1
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000036110 Neuroinflammatory disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
206010060860 Neurological symptom Diseases 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
101710138657 Neurotoxin Proteins 0.000 description 1
206010058667 Oral toxicity Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000007542 Paresis Diseases 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
206010044221 Toxic encephalopathy Diseases 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
210000001642 activated microglia Anatomy 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
238000003556 assay Methods 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
239000002585 base Substances 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
230000003925 brain function Effects 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Inorganic materials [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
ZOMBKNNSYQHRCA-UHFFFAOYSA-J calcium sulfate hemihydrate Chemical compound O.[Ca+2].[Ca+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O ZOMBKNNSYQHRCA-UHFFFAOYSA-J 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000000544 cholinesterase inhibitor Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000001149 cognitive effect Effects 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
210000001653 corpus striatum Anatomy 0.000 description 1
229960005168 croscarmellose Drugs 0.000 description 1
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000010981 drying operation Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
230000002461 excitatory amino acid Effects 0.000 description 1
239000003257 excitatory amino acid Substances 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000012467 final product Substances 0.000 description 1
ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
238000000799 fluorescence microscopy Methods 0.000 description 1
210000003194 forelimb Anatomy 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
231100000734 genotoxic potential Toxicity 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000004914 glial activation Effects 0.000 description 1
230000007946 glucose deprivation Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
239000011507 gypsum plaster Substances 0.000 description 1
230000004886 head movement Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
FAHBNUUHRFUEAI-UHFFFAOYSA-M hydroxidooxidoaluminium Chemical compound O[Al]=O FAHBNUUHRFUEAI-UHFFFAOYSA-M 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
230000003447 ipsilateral effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
230000002025 microglial effect Effects 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
210000001577 neostriatum Anatomy 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
230000003959 neuroinflammation Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000016273 neuron death Effects 0.000 description 1
230000003961 neuronal insult Effects 0.000 description 1
230000000324 neuroprotective effect Effects 0.000 description 1
231100000189 neurotoxic Toxicity 0.000 description 1
230000002887 neurotoxic effect Effects 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
231100000228 neurotoxicity Toxicity 0.000 description 1
239000002581 neurotoxin Substances 0.000 description 1
231100000618 neurotoxin Toxicity 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
231100000418 oral toxicity Toxicity 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
239000008213 purified water Substances 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000013223 sprague-dawley female rat Methods 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000155 toxicity by organ Toxicity 0.000 description 1
230000007675 toxicity by organ Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
229940045145 uridine Drugs 0.000 description 1
230000035899 viability Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)

IL12748797A 1996-07-11 1997-07-01 Use of thiazolidinone derivatives for the preparation of drugs for the treatment of neurodegenerative diseases IL127487A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US2157196P	1996-07-11	1996-07-11
PCT/US1997/011586 WO1998002160A1 (en)	1996-07-11	1997-07-01	Method for treating and preventing neurodegenerative disorders by administering a thiazolidinone

Publications (2)

Publication Number	Publication Date
IL127487A0 IL127487A0 (en)	1999-10-28
IL127487A true IL127487A (en)	2002-04-21

Family

ID=21804973

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL12748797A IL127487A (en)	1996-07-11	1997-07-01	Use of thiazolidinone derivatives for the preparation of drugs for the treatment of neurodegenerative diseases

Country Status (22)

Country	Link
US (1)	US5912259A (de)
EP (1)	EP0914122B1 (de)
JP (1)	JP2001508028A (de)
KR (1)	KR20000023683A (de)
CN (1)	CN1145481C (de)
AT (1)	ATE250416T1 (de)
AU (1)	AU726664B2 (de)
BR (1)	BR9710467A (de)
CA (1)	CA2255073A1 (de)
CO (1)	CO4940509A1 (de)
DE (1)	DE69725147T2 (de)
DK (1)	DK0914122T3 (de)
ES (1)	ES2205247T3 (de)
HR (1)	HRP970362A2 (de)
IL (1)	IL127487A (de)
NO (1)	NO990076L (de)
NZ (1)	NZ332763A (de)
PL (1)	PL331049A1 (de)
PT (1)	PT914122E (de)
TR (1)	TR199900040T2 (de)
WO (1)	WO1998002160A1 (de)
ZA (1)	ZA976142B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003104423A2 (en) *	2002-06-11	2003-12-18	Roy Ogle	Meningeal-derived stem cells
US20110104296A1 (en) *	2008-05-08	2011-05-05	Dipak Kumar Sarkar	Endorphin Therapy Compositions and Methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT83152B (pt) *	1985-08-09	1989-03-30	Lilly Co Eli	Processo para a preparacao de compostos di-t-butilfenoicos
ZA902520B (en) *	1989-04-07	1991-12-24	Lilly Co Eli	Aryl-substituted rhodanine derivatives
US5143928A (en) *	1990-03-27	1992-09-01	Warner-Lambert Company	3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
US5192753A (en) *	1991-04-23	1993-03-09	Mcgeer Patrick L	Anti-rheumatoid arthritic drugs in the treatment of dementia
CZ181493A3 (en) *	1992-09-10	1994-03-16	Lilly Co Eli	The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease
EP0722729A3 (de) *	1995-01-23	1997-11-26	Eli Lilly And Company	Aryl-substituierte Rhodaninen zur Behandlung multipler Sklerose
EP0833622B8 (de) *	1995-06-12	2005-10-12	G.D. Searle & Co.	Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor

1997
- 1997-07-01 DE DE69725147T patent/DE69725147T2/de not_active Expired - Fee Related
- 1997-07-01 NZ NZ332763A patent/NZ332763A/xx unknown
- 1997-07-01 IL IL12748797A patent/IL127487A/en not_active IP Right Cessation
- 1997-07-01 BR BR9710467A patent/BR9710467A/pt not_active Application Discontinuation
- 1997-07-01 AT AT97933264T patent/ATE250416T1/de not_active IP Right Cessation
- 1997-07-01 WO PCT/US1997/011586 patent/WO1998002160A1/en not_active Ceased
- 1997-07-01 TR TR1999/00040T patent/TR199900040T2/xx unknown
- 1997-07-01 ES ES97933264T patent/ES2205247T3/es not_active Expired - Lifetime
- 1997-07-01 DK DK97933264T patent/DK0914122T3/da active
- 1997-07-01 JP JP50606698A patent/JP2001508028A/ja not_active Ceased
- 1997-07-01 PL PL97331049A patent/PL331049A1/xx unknown
- 1997-07-01 CA CA002255073A patent/CA2255073A1/en not_active Abandoned
- 1997-07-01 CN CNB971960429A patent/CN1145481C/zh not_active Expired - Fee Related
- 1997-07-01 AU AU36491/97A patent/AU726664B2/en not_active Ceased
- 1997-07-01 EP EP97933264A patent/EP0914122B1/de not_active Expired - Lifetime
- 1997-07-01 US US09/171,891 patent/US5912259A/en not_active Expired - Fee Related
- 1997-07-01 PT PT97933264T patent/PT914122E/pt unknown
- 1997-07-03 HR HR60/021,571A patent/HRP970362A2/xx not_active Application Discontinuation
- 1997-07-10 CO CO97038493A patent/CO4940509A1/es unknown
- 1997-07-10 ZA ZA9706142A patent/ZA976142B/xx unknown
1999
- 1999-01-08 NO NO990076A patent/NO990076L/no not_active Application Discontinuation
- 1999-01-09 KR KR1019997000140A patent/KR20000023683A/ko not_active Abandoned

Also Published As

Publication number	Publication date
CN1145481C (zh)	2004-04-14
CN1223582A (zh)	1999-07-21
EP0914122A1 (de)	1999-05-12
TR199900040T2 (xx)	1999-04-21
NO990076D0 (no)	1999-01-08
DE69725147T2 (de)	2004-07-22
PT914122E (pt)	2003-12-31
CA2255073A1 (en)	1998-01-22
AU726664B2 (en)	2000-11-16
WO1998002160A1 (en)	1998-01-22
CO4940509A1 (es)	2000-07-24
DK0914122T3 (da)	2003-12-22
JP2001508028A (ja)	2001-06-19
ATE250416T1 (de)	2003-10-15
HRP970362A2 (en)	1998-04-30
HK1020533A1 (en)	2000-05-12
IL127487A0 (en)	1999-10-28
PL331049A1 (en)	1999-06-21
EP0914122B1 (de)	2003-09-24
BR9710467A (pt)	1999-08-17
US5912259A (en)	1999-06-15
AU3649197A (en)	1998-02-09
NO990076L (no)	1999-01-08
ZA976142B (en)	1998-02-02
NZ332763A (en)	2000-07-28
DE69725147D1 (de)	2003-10-30
KR20000023683A (ko)	2000-04-25
ES2205247T3 (es)	2004-05-01

Legal Events

Date	Code	Title
2002-09-12	FF	Patent granted
2002-11-10	KB	Patent renewed
2003-09-17	KB	Patent renewed
2008-03-23	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
KR102014875B1 (ko)	2019-08-27	파킨슨병을 치료하기 위한 신규의 치료적 접근법
JP5249388B2 (ja)	2013-07-31	糖尿病の治療及び予防のためのフタリド誘導体の使用
EP3185859B1 (de)	2019-07-17	Neue therapeutische ansätze zur behandlung von morbus parkinson
NL8802634A (nl)	1989-05-16	Therapeutische preparaten.
TW201609640A (zh)	2016-03-16	吲哚基及吲哚啉基異羥肟酸於治療神經退化病症或認知缺乏之用途
JPH0761923A (ja)	1995-03-07	アルツハイマー病治療剤
JPH0667842B2 (ja)	1994-08-31	基本的うつ病を軽減するためのうつ病治療剤
JP2008526953A (ja)	2008-07-24	炎症性疾患のプラジカンテルでの治療
WO2005107756A1 (en)	2005-11-17	A method for the treatment or prevention of cardiac hypertrophy
TWI777059B (zh)	2022-09-11	肌肉減少症之預防劑及治療劑
EA001325B1 (ru)	2001-02-26	Способы лечения и профилактики интерстициального цистита
CN115154447A (zh)	2022-10-11	一种2,6-二(2-(三氟甲基)苯亚甲基)环己酮在炎症性肠病药物制备中的应用
RU2307651C2 (ru)	2007-10-10	Каппа-опиатные агонисты для лечения заболеваний мочевого пузыря
AU726664B2 (en)	2000-11-16	Method for treating and preventing neurodegenerative disorders by administering a thiazolidinone
TW202116297A (zh)	2021-05-01	組合療法之方法、組成物與套組
KR101887561B1 (ko)	2018-09-06	간염 바이러스에 의해 유발된 간 섬유화의 개선을 위한 약학 조성물
JP5575927B2 (ja)	2014-08-20	ペントキシフィリンの便秘の予防または治療における応用
NL2036681B1 (en)	2024-09-20	Application of Naringin Combined with Rapamycin in the Preparation of Medications for Treating Hyperlipidemia
DK166947B1 (da)	1993-08-09	Forbedrede piroxicamholdige praeparater med antiinflammatorisk virkning
CN112843065B (zh)	2022-03-01	一种用于认知障碍的药物及其制备方法
HK1020533B (en)	2005-04-08	Use of a thiazolidinone in the preparation of a medicament for treating and preventing neurodegenerative disorders
WO2023202439A1 (zh)	2023-10-26	二萜化合物衍生物或其盐在制备防治特应性皮炎的药物中的应用
KR20260021014A (ko)	2026-02-12	근위축성 측삭 경화증(als)의 치료
HUP9903936A2 (hu)	2000-03-28	Tiazolidinonszármazék alkalmazása neurodegenerációs rendellenességek kezelésére és megelőzésére szolgáló gyógyszerkészítmények előállítására
KR20260021653A (ko)	2026-02-13	IgA 매개 질환의 치료 방법에 사용하기 위한 스파르센탄